Work

Sustained Remission With Atezolizumab in a Frail, Geriatric Patient With Advanced‐Stage Large Cell Neuroendocrine Carcinoma Lung

Year: 2025

Type: article

Abstract: Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive cancer primarily found in the lungs but can also occur in other organs. It is characterized by rapid progression and high metastatic potential. We present a case of advanced-stage LCNEC lung in a patient with a poor performance status (PS), requiring oxygen support. Imaging revealed a large right upper lobe mass, lymphadenopathy, with bronchial encasement and invasion into the superior vena cava, leading to SVC syndrome and pleural effusion. Biopsy and immunohistochemistry confirmed LCNEC. Due to the patient's poor PS, treatment began with low-dose single-agent chemotherapy (carboplatin), followed by etoposide and cisplatin after improvement. Local radiation was also administered, and the treatment plan was adjusted to include atezolizumab. After 10 cycles, the patient achieved complete remission, sustained for 6 years. This case highlights the complexities of managing advanced LCNEC in a geriatric patient and the effectiveness of a multidisciplinary approach and immunotherapy.

Source: Case Reports in Oncological Medicine

DOI: 10.1155/crom/2406678

Authors: Mayank Kapoor, Praneet Bedi, Deepak Sundriyal, Ashita Jain, Ujjawal Shriwastav, Amit Sehrawat

Institutions: All India Institute of Medical Sciences Rishikesh, Max Super Speciality Hospital, Tribhuvan University, Chitwan Medical College

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $790